Rigvir Group is a private organization constituted of several companies which have been developing oncolytic virotherapy since 2002. The core elements of the organization strategy are the production of the unique oncolytic ECHO-7 virus Rigvir, maintenance of efficient R&D team, sophisticated manufacturing, drug development and licensing.
We are committed to provide access to virotherapy around the world, saving and improving lives of cancer patients today and in the future. Rigvir Group is the first company in the world to register oncolytic virus and systematically train eligible health care professionals for its clinical use, making us the most experienced organization in the development and clinical practice of oncolytic viruses.
To invent, develop and provide access to advanced biotechnological products that transform the treatment paradigm in oncology - fight cancer effectively and are safe and harmless for patient lives.
Since 2018 we have implemented functional changes to become a biotech company, focusing the resources on production development and manufacturing capacity increase, providing the opportunity for global partnerships regarding product promotion and distribution.
Rigvir Group has achieved recognition from a number of organizations for ongoing efforts in research and innovation, management of the intellectual property, corporate responsibility and business performance (Horizon 2020, EC, ESF and WIPO).
We used support social projects to help patients and protect their rights via Aina Muceniece Virotherapy Foundation.